Consequently, in all four CRC cell lines tested, combination of AZ304 and Cetuximab caused a more potent inhibition of BRAF, ERK, AKT and mTOR signalling pathways, compared with single agents, providing a rationale for the observed synergy in anti-tumour effects. This evidence concerns the gene BRAF and colorectal carcinoma.